Abstract: The present invention provides the identification of biomarker gene sets whose expression levels are useful for predicting a patient's response to a therapeutically effective dose of a Wee1 inhibitor as well the ability to predict said response prior to dosing with the Wee1 inhibitor. Additional uses are also disclosed in the specification.

Abstract: A method for evaluation of a compound comprising the steps of introducing an RSK1 gene into a cell to prepare a cell capable of expressing RSK1, contacting a compound to be evaluated with the cell, and detecting the specific binding of the compound to RSK1; and a compound given by the method. The compound can be used as a potentiator of cisplatin. The method enables to find a gene which acts specifically on a cell of cancer induced by the abnormality in p53 or enhanced MAPK pathway and to evaluate a compound by using the gene.

Abstract: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of S1c25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of S1c25a10 gene or protein. Examination of obesity is performed based on expression levels of S1c25a10 gene or polymorphisms of the gene.

Abstract: The present invention relates to methods for detecting a dysfunctional cancer suppressing gene, particularly p53. In other aspects, the invention provides methods for diagnosing cell proliferative disorders such as cancer by measuring expression of a predetermined target gene. Methods of evaluating the efficacy of a test compound to treat a cell proliferative disorder are also included. Such methods generally rely on the expression levels of a predetermined or targeted gene.

Abstract: The present invention provides polymorphisms of ABCG2 polypeptide and polynucleotide coding therefor, which is related to the intracellular accumulation of indolocarbazole compounds, as well as methods for detecting the polymorphisms, comprising collecting a sample from mammals, and determining a polymorphism of the nucleotide sequence of ABCG2 gene or a polymorphism of the amino acid sequence of ABCG2 polypeptide. In a preferred embodiment of the present invention, the polymorphism of the nucleotide sequence is one or more of single nucleotide polymorphisms at positions selected from the group consisting of 34, 376 and 421 of SEQ ID NO:1, and the polymorphism of the amino acid sequence is one or more of amino acid polymorphisms at positions consisting of 12, 126, and 141 of SEQ ID NO:2.

Abstract: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of Slc25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of Slc25a10 gene or protein. Examination of obesity is performed based on expression levels of Slc25a10 gene or polymorphisms of the gene.

Abstract: The present invention relates to a polypeptide which excretes drugs such as cancer chemotherapeutic agents from a cell and to a gene coding therefor. More specifically, the present invention relates to a method for predicting a drug transport capability of a mammalian cell by determining a single nucleotide polymorphism(s) of ABCG2 gene and/or an amino acid polymorphism(s) of ABCG2 polypeptide and also to a polynucleotide, polypeptide, kit, and the like used for the method.

Abstract: The present invention relates to G0 transgenic chimeric birds capable of transmitting a desired gene or gene arrangement to offspring with very high efficiency and to a method of producing the same, and relates to G0 transgenic chimeric birds having a desired gene or gene arrangement in germ cells with very high efficiency and to a method of producing the same. A G0 transgenic chimeric bird which comprises a G0 transgenic chimeric bird resulting from gene transduction using a replication-defective retrovirus vector and that the efficiency of transgene transmission to G1 is not less than 10%.

Abstract: The invention has a object to provide a G0 transgenic chimera bird which can efficiently accumulate the useful protein in eggs of a female bird in which the protein is expressed in an oviduct-specific manner and can accumulate even a toxic protein in eggs with no ill effect for birds, and a transgenic bird and a method of producing them. The above object can be attained by providing a G0 transgenic chimera bird and transgenic bird obtained by introducing a replication-defective retrovirus vector coding for a useful protein by an oviduct-specific expression promoter.